Sun Pharma acquires anti-inflammatory brands from Aksigen Hospital Care
Publicly-listed Sun Pharmaceutical Industries has acquired three anti-inflammatory drug brands - Disperzyme, Disperzyme-CD and Phlogam - from fellow Mumbai-based Aksigen Hospital Care. The drugs are for treating post-operative inflammation in patients undergoing minor surgery and dental procedures. It is claimed that Disperzyme and Phlogam are the first enzyme-bioflavonoid combination of Trypsin, Bromelain and Rutoside (TBR) to complete a clinical study in India and get DCGI approval. The brands were registered and launched in India by Aksigen in 2013
Want to receive such news items in your inbox? Click Here to sign up for a trial.